Abstract
Cetuximab (C), a chimeric monoclonal antibody that binds epidermal growth factor receptor (EGFR), is active against androgen-independent prostate cancer cell lines and might enhance the activity of chemotherapy. The efficacy of combining cetuximab with mitoxantrone (M) plus prednisone (MP) was evaluated in progressive metastatic castrate-resistant prostate cancer (CRPC) after receiving docetaxel. Patients with progression after receiving docetaxel were eligible and randomized 2:1 to CMP or MP. Therapy was mitoxantrone 12 mg/m(2) intravenously (I.V.) on day 1, oral prednisone 10 mg daily in both arms, and cetuximab 250 mg/m(2) I.V. (400 mg/m(2) day 1, cycle 1) on days 1, 8, and 15 in the CMP arm. Cycles were repeated every 21 days. Radiologic assessments of disease and PSA (prostate-specific antigen) occurred every 4 cycles. The primary endpoint was time to progression (TTP). A total of 115 patients were enrolled, 75 in the CMP and 40 in the MP arm: the median TTP was 4.9 and 6.6 months, respectively; the measurable disease response rate was 2% and 4%, the PSA response rate 7.7% and 17.6%, and median survival 11.9 and 15.7 months, respectively. Key grade 3-4 toxicities were neutropenia 44% and 25.6%, anemia 6.7% and 7.7%, thromb...Continue Reading
References
Apr 1, 1995·The Journal of Clinical Investigation·X WuJ Mendelsohn
Aug 18, 1993·Journal of the National Cancer Institute·J BaselgaJ Mendelsohn
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzRobert J Mayer
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford
Jan 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ki Young ChungLeonard B Saltz
Feb 10, 2006·The New England Journal of Medicine·James A BonnerK Kian Ang
Feb 10, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paula M FracassoChristopher R Garrett
Mar 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jun KuraiEiji Shimizu
Jun 20, 2007·Cancer·Jonathan E RosenbergEric J Small
Jul 31, 2007·BMC Cancer·Mitchell GrossDavid B Agus
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shirin Khambata-FordDavid J Mauro
Nov 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thorsten SchlommAndreas Erbersdobler
Jan 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Astrid LièvrePierre Laurent-Puig
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I ScherUNKNOWN Prostate Cancer Clinical Trials Working Group
Apr 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alberto F SobreroHoward A Burris
May 20, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D R BertholdUNKNOWN TAX 327 Investigators
Aug 21, 2008·Oncology·Francesco BoccardoAlberto Lapini
Oct 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Johann S de BonoDerek Raghavan
Feb 7, 2009·The New England Journal of Medicine·Jolien TolCornelis J A Punt
May 5, 2009·Lancet·Robert PirkerUNKNOWN FLEX Study Team
Oct 10, 2009·Clinical Genitourinary Cancer·Susan F SlovinHoward I Scher
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre Laurent-PuigFrédérique Penault-Llorca
Jul 9, 2010·CA: a Cancer Journal for Clinicians·Ahmedin JemalElizabeth Ward
Sep 8, 2010·The New England Journal of Medicine·Philip W KantoffUNKNOWN IMPACT Study Investigators
Oct 5, 2010·Lancet·Johann Sebastian de BonoUNKNOWN TROPIC Investigators
Citations
Apr 13, 2013·PharmacoEconomics·Ben KearnsChris Littlewood
Jul 17, 2013·Nature Reviews. Urology·Pavel Sluka, Ian D Davis
Feb 5, 2014·Future Oncology·L Rhoda MolifeJohann S de Bono
May 4, 2016·Oncoimmunology·Joyce M van Dodewaard-de JongAlfons J M van den Eertwegh
Mar 29, 2014·Investigational New Drugs·Arun A AzadKim N Chi
Jun 25, 2013·The Journal of Steroid Biochemistry and Molecular Biology·Isabel HeideggerHelmut Klocker
Oct 8, 2014·Cancer Treatment Reviews·Tomohiro FunakoshiKazuo Tamura
Aug 21, 2014·Critical Reviews in Oncology/hematology·Omar Abdel-Rahman, Mona Fouad
Jun 28, 2016·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·C P EscalanteUNKNOWN Epidemiology Section of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer, 2013
Jan 25, 2017·Nature Reviews. Urology·Antonello VecciaOrazio Caffo
Jun 13, 2017·Current Medical Research and Opinion·Nicholas SummersOliver Sartor
Jan 9, 2019·Cancer·Guru SonpavdeMichael B Lilly
Feb 16, 2013·British Journal of Cancer·N C TebbuttUNKNOWN Australasian Gastro-Intestinal Trials Group (AGITG)
Dec 7, 2018·World Journal of Urology·Matteo FerroCarlo Buonerba
Jul 15, 2018·Cancer Chemotherapy and Pharmacology·Jing Li, Hengxiu Yan
Feb 25, 2020·Journal of Oncology·Adrianna RutkowskaPiotr Rieske
Sep 15, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Richard CathomasUNKNOWN Swiss Group for Clinical Cancer Research SAKK
Mar 7, 2021·Cancers·Amaal Ali, George Kulik